13F Holdings
中文EN

XTLB XTL BIOPHARMACEUTICALS LTD IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1023549

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY42.4%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin0.7%
Operating margin-481.6%
Net margin-227.7%
FCF margin-370.7%
EBITDA margin—

Returns

ROE-26.8%
ROA-18.7%
ROIC (approx.)-58.3%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets36.4%
Debt / equity0.00x
Current ratio0.61x
Interest coverage-77.57x

Cash quality & payout

Operating cash flow / net income1.58x
Accruals ratio10.8%
Payout ratio—
Capex / revenue12.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31FY2020*2020-12-31
Income statement
Revenue$451,000————
Cost of revenue$448,000————
Gross profit$3,000————
R&D expense$98,000$31,000$30,000$30,000$38,000
SG&A expense$1.59M$734,000$850,000$1.00M$910,000
Operating income-$2.17M-$765,000-$880,000-$1.03M-$948,000
Interest expense$28,000—$1.56M$21,000$2.19M
Pretax income-$1.16M-$1.78M-$1.35M——
Income tax-$130,000————
Net income-$1.03M-$1.78M-$1.35M$435,000-$2.95M
EPS (basic)-0.00-0.00-0.000.00-0.01
EPS (diluted)-0.00-0.00-0.000.00-0.01
Weighted avg. shares (diluted)704.16M544.91M544.91M615.55M514.21M
Balance sheet
Cash & equivalents$371,000$1.40M$2.09M$2.97M$3.63M
Short-term investments——$1.63M$3.16M$2.41M
Receivables$99,000————
Current assets$1.34M$2.05M$3.81M$6.24M$6.12M
PP&E, netmay include right-of-use assets (IFRS)$187,000————
Goodwill$3.19M————
Intangibles$3.82M$380,000$380,000$380,000$380,000
Total assets$8.55M$2.43M$4.19M$6.62M$6.50M
Current liabilities$2.21M$206,000———
Short-term debt$138,000————
Total liabilities$3.12M$206,000$187,000$1.28M$2.89M
Shareholders' equity$5.43M$2.22M$4.00M$5.33M$3.61M
Shares outstanding881.39M544.91M544.91M544.91M514.21M
Cash flow statement
Operating cash flow-$1.62M-$707,000-$901,000-$1.05M-$850,000
Capital expenditure$54,000———$1,000
Free cash flow-$1.67M———-$851,000
Investing cash flow-$844,000$41,000$36,000$8,000$32,000
Financing cash flow$1.45M——$385,000—
Stock-based compensation$264,000$3,000$14,000$37,000$51,000

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.